Anticipating Ixo-vec 9-month data, Adverum Biotechnologies stock retains Buy rating By Investing.com

On Tuesday, H.C. Wainwright maintained a Buy rating on Adverum Biotechnologies (NASDAQ:), with a price target of $30.00. The firm is looking forward to the nine-month analysis from the Phase 2 LUNA trial of Ixo-vec, a gene therapy candidate for wet age-related macular degeneration (AMD (NASDAQ:)). This upcoming analysis in the fourth quarter of 2024 is expected to provide further validation and consistent safety data for Ixo-vec.

The nine-month results are seen as a critical step in de-risking the program before the full 52-week primary endpoint analysis, which is anticipated in the first quarter of 2025. The firm also expects an update on the Phase 3 pivotal trial design later in the fourth quarter of 2024, following the selection of the 6E10 vg/eye dose for Phase 3 development.

Recent data from the 26-week interim analysis of the LUNA trial has shown promising results in reducing treatment burden. At the 26-week mark, a significant percentage of patients who previously required frequent anti-VEGF injections were injection-free after receiving Ixo-vec. The 6E10 dosing led to a 90% reduction in mean annualized anti-VEGF injections, while the 2E11 dosing achieved a 95% reduction.

These findings not only suggest a potential best-in-class profile for Ixo-vec but also indicate maintained visual acuity and fluid control outcomes at both dose levels. With these positive interim results and the anticipation of upcoming data, H.C. Wainwright reaffirms its Buy rating and $30 price target on Adverum Biotechnologies.

In other recent news, Adverum Biotechnologies has been awarded the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration for its gene therapy product candidate, Ixo-vec.

This therapy is currently under evaluation in the Phase 2 LUNA clinical trial and the Phase 1 OPTIC extension study for the treatment of wet age-related macular degeneration (wet AMD). In addition to the RMAT, Ixo-vec has received Fast Track designation from the FDA and PRIME designation from the European Medicines Agency.

Adverum has also undergone changes in its leadership team, with the appointment of Dr. Rabia Gurses Ozden as the new Chief Medical Officer and the addition of Dr. Szilárd Kiss to its Board of Directors.

On the other hand, analyst firm TD Cowen maintained a Buy rating on Adverum shares, following the presentation of 26-week data from its Phase II LUNA study. Meanwhile, Oppenheimer initiated coverage on Adverum with an Outperform rating, reinforcing the gene therapy’s commercial potential.

However, RBC Capital Markets has lowered the company’s share price target, maintaining a cautious stance due to Adverum’s past clinical challenges.

InvestingPro Insights

As Adverum Biotechnologies (NASDAQ:ADVM) progresses with its Phase 2 LUNA trial, real-time data from InvestingPro underscores key financial metrics that investors may find pertinent. The company’s market capitalization stands at a modest $134.71 million, reflecting its status as a smaller player within the biotech sector. Despite a challenging financial performance over the last twelve months, with a reported gross profit of -$72.03 million and an operating income adjusted to -$120.37 million, the company holds more cash than debt, which can be a positive sign of liquidity. This liquidity is further evidenced by the fact that liquid assets exceed short-term obligations, according to an InvestingPro Tip.

Investors should note that analysts do not expect the company to be profitable this year, as indicated by a negative P/E ratio of -0.69. However, another InvestingPro Tip suggests that analysts anticipate sales growth in the current year, which could be a harbinger of potential upside if the company’s trials yield positive results. The stock has been trading near its 52-week low, which might appeal to value investors looking for an entry point, though caution is warranted given the stock’s significant decline over the last six months of -71.66%.

For those seeking a deeper dive into the company’s prospects and financial health, InvestingPro offers additional tips that can provide a more nuanced understanding of Adverum Biotechnologies. For further insights, including more InvestingPro Tips, visit https://www.investing.com/pro/ADVM.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.